ArticleNature communications2024
Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Survey on COVID-19 Vaccination among Pediatric Cancer Patients and Their Parents: A Single-Center Study from Korea.Infection & chemotherapy · 2026Article
- Mechanisms underlying immunodynamics of layered defenses elicited by mRNA vaccination in children.BMC medicine · 2026Article
- Effectiveness of COVID-19 Vaccine Boosters in Children Across Pandemic and Endemic Periods.Microorganisms · 2026Article
- Adverse events following SARS-CoV-2 mRNA vaccination in norwegian adolescents.Scientific reports · 2026Article
- Advancing the Tendinopathy Triad: Comment on "Tendinopathy: The Interplay Between Mechanical Stress, Inflammation, and Vascularity".Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- mRNA vaccine expressing enterovirus D68 virus-like particles induces potent neutralizing antibodies and protects against infection.Molecular therapy. Nucleic acids · 2025Article
- Top 10 drugs most frequently associated with adverse events of myocarditis and pericarditis.Scientific reports · 2025Article
- The COVID-19 pandemic increased the incidence of newly diagnosed cancers: evidence from a large cohort study in Southern Italy.BMC medicine · 2025Article
- The Long-Term Tolerability of BNT162b2 in Children and Adolescents (the CoVacU18 Study).Deutsches Arzteblatt international · 2025Article
- Investigating the association between SARS-CoV-2 infection, COVID-19 vaccination, and autoimmune diseases in a pediatric population: a comprehensive analysis.Pediatric rheumatology online journal · 2025Article
- Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle.Vaccines · 2025Review
- The COVID-19 pandemic in children and young people during 2022-24: what new did we learn?Journal of global health · 2025Article
- Enhancing RNA vaccine safety through localized delivery strategies.Vaccine insights · 2025Article
- COVID-19 vaccines and neurological disorders: A narrative review of immune responses and adverse reactions.AIMS neuroscience · 2025Review
- COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province.EXCLI journal · 2025Article
- Article
- Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan.Global health & medicine · 2024Article
- Myocarditis Associated with COVID-19 Vaccination.Vaccines · 2024Review
- Article
- Identifying and reducing risks of neurological complications associated with vaccination.Nature reviews. Neurology · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
Abstract
The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1-42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0-5) and 5 (95%CI 3-6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0-23) hospitalisations with epilepsy and 4 (95%CI 0-6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.